InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,716.80
(
0.19%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.36
(
0.17%
)
Bitcoin
62,803.00
(
-0.16%
)
Post# of 879
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trend-Setter

Send PM Follow Ignore
Followers 13
Posts 1022
Boards Moderated 0
Alias Born 07/19/2013

Trend-Setter

Re: None

Tuesday, 10/22/2019 12:49:32 PM

Tuesday, October 22, 2019 12:49:32 PM

Post# of 879
Tailwinds’ Take: the endpoints for this trial, time to recurrence and volume removed, should be easy for a well-known drug like Terlipressin to achieve. Next step for BIVI is obtaining funding. Once funded, this could be one of the lowest risk clinical trials we’ve seen.

https://tailwindsresearch.com/2019/10/biovie-submits-protocol-for-phase-2b-3-refractory-ascites-study-to-fda/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent BIVI News
More BIVI News
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!